FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256392317> ?p ?o ?g. }

• W4256392317 endingPage "1260" @default.
• W4256392317 startingPage "1260" @default.
• W4256392317 abstract "Abstract Abstract 1260 Angiopoietin-2 (Ang2) is a 75 kDa secreted glycoprotein able to bind to the receptor tyrosine kinase Tie-2 and detectable especially in vascular remodeling sites. High Ang2 levels are observed in highly vascularized tumors and may play a role in tumor angiogenesis. We have recently demonstrated that Ang2 protein secreted by CLL cells increases in vivo and in vitro angiogenesis and that, in a small CLL cohort, higher Ang2 mRNA expression is associated with advanced stage disease and shorter progression-free survival. In order to further investigate potential prognostic role of Ang2 in CLL, we measured Ang2 plasma levels using an ELISA-based method, in a large multicentric series: 42(13.3%) of 316 analyzed patients had previously received treatment and an additional 53(16.8%) required therapy during the study course, with a median TTFT of 40 months. Ang2 dosage ranged from 972 to 17281 pg/ml (median, 2061 pg/ml). The best cut-off point, generated by ROC analysis and Youden's index (state variable, treating), was 2460 pg/ml and divided our cohort in two subsets (high Ang2 and low Ang2) composed by 100 (31.6%) and 216 (68.4%) patients, respectively. The median TTFT resulted significantly shorter (P<.001) in the high Ang2 subgroup (77.5 months) than in the low one (179.2 months). Cox univariate analysis identified Ang2 ≥ 2460 pg/ml as a predictor of reduced TTFT (HR 2.437; 95%CI 1.621 - 3.664, P<.001) as well as advanced Binet stage, unmutated IGHV status, high CD38, ZAP-70 and CD49d expression, intermediate/high cytogenetic risk and high β2 microglobulin (P<.001 in all instances). Multivariate analysis confirmed that high Ang2 levels were an independent prognosticator for TTFT (HR 1.739; 95%CI 1.059 – 2.857; P=.029) together with inter/high FISH risk (P<.001) and unmutated IGHV status (P= .002). Comparing OS between high Ang2 and low Ang2 subgroup, we found that 26% of high Ang2 patients were dead at 10-years from diagnosis, in contrast with 7% of low Ang2 ones (P=.002). In univariate analysis, Ang2 ≥ 2460 pg/ml resulted to be a predictor of poor OS (HR 3.566; 95%CI 1.496 – 8.499; P=.004) as well as most of the other known unfavorable prognosticators. Significant association was found between high Ang2 plasma level and Binet stages B-C (P<.001), high β2 microglobulin (P<.001), unmutated IGHV status (P<.001), high CD38 and ZAP-70 expression (P<.001 and P=.003, respectively) and inter/high cytogenetic risk (P=.005). However, a relevant percentage of patients showed high Ang2 levels in the presence of favorable markers and vice versa: in this cases, defined as discordant, Ang2 helps to refine prognosis identifying CLL subgroup with precocious need for treatment and reduced survival despite characterized by favorable prognostic factors. In order to evaluate if Ang2 dosage could be modulated by treatment, we compare Ang2 level of plasma samples collected before (n=53) and after (n=42) the first therapy and we did not find any statistical difference (P=.6). Finally, we studied two serial plasma samples collected from 36 patients (median interval, 19 months; range, 3-30 months) and we did not find significant changes in Ang2 level between the two measurements, both for the 7 patients treated inside this interval (P=.612) and for the 29 cases untreated (P=.347). These data first demonstrate the prognostic role of Ang2 plasma level for TTFT and OS in CLL, and shows how Ang2 contributes to refine the prognostic assessment of CLL. The measurement of serial plasma samples demonstrates that Ang2 levels are quite stable during the disease course and are not modulated by current treatments: this suggests that higher Ang2 secretion could be a peculiar biological characteristic of more aggressive CLL, already present in the first disease steps. Our study implies a simple ELISA method, with a high reproducibility and reliability of results, that could be used both for clinical practice and for further studies, in order to better understand CLL pathogenesis and identify new target therapies. Since several molecules targeting microenvironment and angiogenesis are developing in clinical trials for CLL, it could be very interesting to evaluate if they are able to modulate Ang2 secretion and modify the disease clinical aggressiveness. Disclosures No relevant conflicts of interest to declare." @default.
• W4256392317 created "2022-05-12" @default.
• W4256392317 creator A5003361632 @default.
• W4256392317 creator A5004399775 @default.
• W4256392317 creator A5015790909 @default.
• W4256392317 creator A5025869007 @default.
• W4256392317 creator A5031970751 @default.
• W4256392317 creator A5036055911 @default.
• W4256392317 creator A5041745367 @default.
• W4256392317 creator A5049254574 @default.
• W4256392317 creator A5055389581 @default.
• W4256392317 creator A5061494785 @default.
• W4256392317 creator A5062047451 @default.
• W4256392317 creator A5068707385 @default.
• W4256392317 creator A5073179633 @default.
• W4256392317 creator A5073994020 @default.
• W4256392317 creator A5078295579 @default.
• W4256392317 creator A5078308878 @default.
• W4256392317 creator A5080861890 @default.
• W4256392317 date "2009-11-20" @default.
• W4256392317 modified "2023-10-17" @default.
• W4256392317 title "Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia." @default.
• W4256392317 doi "https://doi.org/10.1182/blood.v114.22.1260.1260" @default.
• W4256392317 hasPublicationYear "2009" @default.
• W4256392317 type Work @default.
• W4256392317 citedByCount "0" @default.
• W4256392317 crossrefType "journal-article" @default.
• W4256392317 hasAuthorship W4256392317A5003361632 @default.
• W4256392317 hasAuthorship W4256392317A5004399775 @default.
• W4256392317 hasAuthorship W4256392317A5015790909 @default.
• W4256392317 hasAuthorship W4256392317A5025869007 @default.
• W4256392317 hasAuthorship W4256392317A5031970751 @default.
• W4256392317 hasAuthorship W4256392317A5036055911 @default.
• W4256392317 hasAuthorship W4256392317A5041745367 @default.
• W4256392317 hasAuthorship W4256392317A5049254574 @default.
• W4256392317 hasAuthorship W4256392317A5055389581 @default.
• W4256392317 hasAuthorship W4256392317A5061494785 @default.
• W4256392317 hasAuthorship W4256392317A5062047451 @default.
• W4256392317 hasAuthorship W4256392317A5068707385 @default.
• W4256392317 hasAuthorship W4256392317A5073179633 @default.
• W4256392317 hasAuthorship W4256392317A5073994020 @default.
• W4256392317 hasAuthorship W4256392317A5078295579 @default.
• W4256392317 hasAuthorship W4256392317A5078308878 @default.
• W4256392317 hasAuthorship W4256392317A5080861890 @default.
• W4256392317 hasConcept C10515644 @default.
• W4256392317 hasConcept C126322002 @default.
• W4256392317 hasConcept C143998085 @default.
• W4256392317 hasConcept C144301174 @default.
• W4256392317 hasConcept C167734588 @default.
• W4256392317 hasConcept C2777025900 @default.
• W4256392317 hasConcept C2780394083 @default.
• W4256392317 hasConcept C2909146873 @default.
• W4256392317 hasConcept C38180746 @default.
• W4256392317 hasConcept C50382708 @default.
• W4256392317 hasConcept C71924100 @default.
• W4256392317 hasConcept C72563966 @default.
• W4256392317 hasConcept C90924648 @default.
• W4256392317 hasConceptScore W4256392317C10515644 @default.
• W4256392317 hasConceptScore W4256392317C126322002 @default.
• W4256392317 hasConceptScore W4256392317C143998085 @default.
• W4256392317 hasConceptScore W4256392317C144301174 @default.
• W4256392317 hasConceptScore W4256392317C167734588 @default.
• W4256392317 hasConceptScore W4256392317C2777025900 @default.
• W4256392317 hasConceptScore W4256392317C2780394083 @default.
• W4256392317 hasConceptScore W4256392317C2909146873 @default.
• W4256392317 hasConceptScore W4256392317C38180746 @default.
• W4256392317 hasConceptScore W4256392317C50382708 @default.
• W4256392317 hasConceptScore W4256392317C71924100 @default.
• W4256392317 hasConceptScore W4256392317C72563966 @default.
• W4256392317 hasConceptScore W4256392317C90924648 @default.
• W4256392317 hasIssue "22" @default.
• W4256392317 hasLocation W42563923171 @default.
• W4256392317 hasOpenAccess W4256392317 @default.
• W4256392317 hasPrimaryLocation W42563923171 @default.
• W4256392317 hasRelatedWork W11607516 @default.
• W4256392317 hasRelatedWork W14070955 @default.
• W4256392317 hasRelatedWork W18431496 @default.
• W4256392317 hasRelatedWork W19656460 @default.
• W4256392317 hasRelatedWork W20555425 @default.
• W4256392317 hasRelatedWork W20905478 @default.
• W4256392317 hasRelatedWork W24410202 @default.
• W4256392317 hasRelatedWork W2621116 @default.
• W4256392317 hasRelatedWork W4310718 @default.
• W4256392317 hasRelatedWork W5346711 @default.
• W4256392317 hasVolume "114" @default.
• W4256392317 isParatext "false" @default.
• W4256392317 isRetracted "false" @default.
• W4256392317 workType "article" @default.